BERWYN, Pa., Jan. 27, 2017 /PRNewswire/ -- RM LAW, P.C.
announces that a class action lawsuit has been filed in United
States District Court for the District of New Jersey on behalf of all persons or
entities that purchased Agile Therapeutics, Inc. ("Agile" or the
"Company") (NASDAQ: AGRX) securities between March 9, 2016 and January
3, 2017, inclusive (the "Class Period").
Agile shareholders may, no later than March 7, 2017, move the Court for appointment as
a lead plaintiff of the Class. If you purchased shares of
Agile and would like to learn more about these claims or if you
wish to discuss these matters and have any questions concerning
this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844)
291-9299 or to sign up online, visit:
www.maniskas.com.
Agile, a specialty pharmaceutical company, focuses on the
development and commercialization of prescription contraceptive
products for women.
The Complaint alleges that throughout the Class Period
Defendants made false and/or misleading statements and/or failed to
disclose that (1) that the Twirla contraceptive patch had an
efficacy rating that fell below peer group standards; (2) that over
half of patients in its "Secure" Phase 3 Study discontinued the
study early; (3) that the Twirla patch therefore allegedly had a
slight chance of FDA approval; and (4) that, as a result of the
foregoing, Defendants' statements about Agile's business,
operations, and prospects, were false and misleading and/or lacked
a reasonable basis.
On January 3, 2017, Agile
disclosed statistical information pertaining to its Phase 3 SECURE
study analyzing the Company's combined hormonal contraceptive patch
Twirla. The study, which was initiated at the request of the FDA,
comes after the FDA rejected Agile's initial marketing application
back in 2013. The Company cited "positive top-line results" in the
study, yet reported an efficacy measure that failed to meet the
standard set by other approved contraceptive patches. Additionally,
51.4% of subjects opted to discontinue the study.
On this news, Agile stock fell nearly 48% on January 4, 2017, closing at $2.63/share, down $2.37/share.
If you are a member of the class, you may, no later than
March 7, 2017, request that the Court
appoint you as lead plaintiff of the class. A lead plaintiff
is a representative party that acts on behalf of other class
members in directing the litigation. In order to be appointed
lead plaintiff, the Court must determine that the class member's
claim is typical of the claims of other class members, and that the
class member will adequately represent the class. Under
certain circumstances, one or more class members may together serve
as "lead plaintiff." Your ability to share in any recovery is
not, however, affected by the decision whether or not to serve as a
lead plaintiff. You may retain RM LAW, P.C. or other counsel
of your choice, to serve as your counsel in this action.
For more information regarding this, please contact RM LAW, P.C.
(Richard A. Maniskas, Esquire)
toll-free at (844) 291-9299 or by email at rm@maniskas.com or
visit: www.maniskas.com. For more information about class
action cases in general or to learn more about RM LAW, P.C. please
visit our website: www.maniskas.com.
RM LAW, P.C. is a national shareholder litigation firm. RM
LAW, P.C. is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal
courts nationwide.
CONTACT:
RM LAW, P.C.
Richard A. Maniskas,
Esquire
1055 Westlakes Dr., Ste.
3112
Berwyn, PA
19312
484-324-6800
844-291-9299
www.maniskas.com
rm@maniskas.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rm-law-announces-class-action-lawsuit-against-agile-therapeutics-inc-300398220.html
SOURCE RM LAW, P.C.